Evidence analysisNovember 18, 2026Evidence

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment

What is established

Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella pneumoniae and Escherichia coli, are increasingly recognized as critical pathogens contributing to healthcare-associated infections. These bacteria are resistant to carbapenems, a class of last-resort antibiotics often used against multidrug-resistant infections. The prevalence of CRE in the European Union (EU) and European Economic Area (EEA) is rising, leading to more bloodstream infections (BSIs) with significant mortality risk. Clinical management of such infections is complicated by limited available effective antimicrobials.

Key mechanisms driving resistance include the production of carbapenemase enzymes, which deactivate carbapenems. Among these, New Delhi metallo-beta-lactamase (NDM) carbapenemases have become increasingly prevalent. Additionally, the bacteria are acquiring virulence factors such as yersiniabactin and aerobactin, which may enhance their ability to cause infection and persist in hosts.

Current treatments, including recently approved beta-lactam/beta-lactamase inhibitor combinations, face diminished effectiveness against some CRE strains, especially those producing NDM carbapenemases. Infection prevention and control (IPC) measures, antimicrobial stewardship, and rapid laboratory diagnostics are established priorities to contain spread and improve treatment outcomes.

What the source claims

The European Centre for Disease Prevention and Control (ECDC) released a rapid risk assessment in November 2026 detailing a worsening epidemiological situation of CRE in the EU/EEA. The assessment is based on recent European genomic surveillance, notably the 2025 CRE survey, which documents the following points:

  • Ongoing increases in CRE incidence, particularly bloodstream infections caused by carbapenem-resistant K. pneumoniae.
  • A shift in carbapenemase types with a rise in NDM carbapenemase prevalence among K. pneumoniae isolates.
  • An increasing presence of virulence factors, such as yersiniabactin and aerobactin, in CRE strains.
  • Dissemination of CRE strains of E. coli carrying the blaOXA-244 gene.
  • High attributable mortality from CRE bloodstream infections, linked to treatment delays and limited therapeutic options.
  • A call for urgent enhanced national coordination including establishing CRE control teams and national action plans.
  • Recommendations for reinforced IPC practices emphasizing hand hygiene, screening, communication, and training in healthcare settings.
  • Advocacy for strengthening laboratory capacity for rapid detection, molecular characterization, and genomic surveillance to guide outbreak control.
  • Promotion of antimicrobial stewardship to preserve existing and new treatment options, including ensuring access to effective drugs active against NDM-producing Enterobacterales.
  • Investment in research for novel treatment and control methods.

What may be missing from the usual framing

The ECDC’s assessment is focused on clinical and public health perspectives and does not extensively address social determinants or systemic healthcare factors driving the spread of CRE. For example:

  • The role of antibiotic usage patterns in community and agriculture outside of healthcare is not deeply analyzed.
  • Economic drivers influencing hospital infection control policies and resource allocation are not discussed.
  • Potential disparities in healthcare infrastructure and diagnostic capabilities among EU/EEA countries, which affect detection and response efficacy, receive limited attention.

Additionally, while the assessment highlights the rise of virulence factors, it does not expand on the potential mechanisms linking resistance and virulence evolution nor the implications for community transmission outside hospital settings.

Competing evidence or uncertainty

The ECDC report relies heavily on genomic surveillance data and national laboratory reports, which have limitations in completeness and timeliness. Some uncertainties include:

  • The full extent of community-level CRE spread remains unclear due to historically hospital-focused surveillance.
  • There is limited evidence on the long-term effectiveness of recently approved antimicrobials against emerging NDM-producing CRE variants, given rapid bacterial evolution.
  • The impact of differing national policies on antibiotic use and infection control creates variability in CRE prevalence and outcomes, suggesting heterogeneity across the EU/EEA.
  • The translation of genomic findings into clinical practice for outbreak control requires further evaluation, including cost-effectiveness considerations.

More broadly, while ECDC stresses a “high risk” scenario, quantitative projections of future burden and cost are not presented, leaving some practical planning aspects uncertain.

Why it matters

Antimicrobial resistance represents a significant threat to healthcare systems worldwide; CRE are among the most concerning pathogens due to their resistance to critical antibiotics and association with high mortality infections. Persistent CRE dissemination can lead to:

  • Increased deaths and complications from bloodstream and other severe infections.
  • Loss of effective treatment options, forcing reliance on older, more toxic, or less efficient drugs.
  • Higher healthcare costs from extended hospital stays, intensive care needs, and complex treatments.
  • Greater risk of outbreaks within healthcare facilities, reducing capacity and compromising care quality.
  • Potential spillover into community settings, complicating public health responses.

The ECDC’s findings underline the urgency for coordinated, multi-level interventions including surveillance, laboratory capacity, public health infrastructure, stewardship programs, and innovation in therapeutics.

What to verify next

  • Further independent validation of the CRE incidence trends, including data from different EU/EEA countries, to assess regional variations and drivers.
  • Effectiveness and implementation rates of recommended infection prevention and control measures in diverse healthcare environments.
  • Clinical outcomes of patients treated with novel antimicrobials, particularly against NDM-producing CRE strains, drawing on real-world studies beyond initial approvals.
  • Research progress on understanding the linkage between virulence factors acquisition and resistance development in CRE.
  • Evaluation of community surveillance initiatives to detect and manage CRE outside hospital settings.

Readers are encouraged to consult the original ECDC rapid risk assessment to explore detailed data, methodology, and full recommendations. Careful consideration of evolving evidence and context-specific conditions is essential for informed response strategies.

Source & verification

Primary source: Scientific and technical publications · November 18, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…